FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220900274> ?p ?o ?g. }

• W4220900274 abstract "Abstract Gonadotropin-releasing hormone (GnRH) analogues are commonly used in clinical practice to prevent premature luteinizing hormone (LH) surge during In-Vitro Fertilization/ Intra-Cytoplasmic Sperm Injection (IVF/ICSI) cycles. This review aimed to summarize the available evidence comparing the effects of conventional GnRH antagonist protocols, the most commonly used GnRH antagonist protocols, and GnRH agonist protocols on IVF/ICSI outcomes in women with polycystic ovary syndrome (PCOS). A comprehensive electronic search was carried out in Pubmed, Cochrane CENTRAL, Scopus, Web of Science, CINAHL, TRIP, ClinicalTrials.gov and ISRCTN registry from inception until 24 November 2020 without any language or date restrictions. In addition, reference lists of eligible studies and previous meta-analyses were hand-searched to identify relevant studies. Eligible randomized controlled trials were those designed to compare the effects of conventional GnRH antagonist protocols and GnRH agonist protocols on IVF/ICSI outcomes in PCOS subjects. The Cochrane ROB 2.0 tool was used to assess the risk of bias of each study, and the GRADE assessment was used to evaluate the overall quality of evidence. Data synthesis and analyses were done using Review Manager 5.3 with the assistance of Revman Web. A random-effects model was used for all meta-analysis. Dichotomous outcomes were reported as Relative Risk (RR) and continuous outcomes as Weighted Mean Difference (WMD), both with 95% CIs. The primary outcomes were Live birth rate, Ongoing pregnancy rate, and Ovarian hyperstimulation syndrome (OHSS) rate. Other IVF outcomes were considered secondary outcomes. We included ten studies with 1214 randomized PCOS women. Using GnRH antagonist protocols led to a significantly lower OHSS rate (RR = 0.58; 95% CI: [0.44 to 0.77], P = 0.0002), shorter stimulation duration (WMD = − 0.91; 95% CI: [-1.45 to − 0.37] day, P = 0.0009), lower gonadotropin consumption (WMD = − 221.36; 95% CI: [− 332.28 to − 110.45] IU, P < 0.0001), lower E2 levels on hCG day (WMD = − 259.21; 95% CI: [− 485.81 to − 32.60] pg/ml, P = 0.02), thinner endometrial thickness on hCG day (WMD = − 0.73; 95% CI: [− 1.17 to − 0.29] mm, P = 0.001), and lower number of retrieved oocytes (WMD = − 1.82; 95% CI: [− 3.48 to − 0.15] oocytes, P = 0.03). However, no significant differences in live birth rate, ongoing pregnancy rate, clinical pregnancy rate, multiple pregnancy rate, miscarriage rate and cycle cancellation rate were seen between the GnRH antagonist protocols and the long GnRH agonist one. Although more cycles were cancelled due to poor ovarian response in the GnRH antagonist protocol (RR = 4.63; 95% CI: [1.49 to 14.41], P = 0.008), similar rates of cancellation due to risk of OHSS were noticed in both groups. The differences in IVF/ICSI outcomes may arise from the different patterns of gonadotropins suppression that the GnRH analogues exhibit during the early follicular phase of IVF/ICSI cycles and the divergent direct impacts of these analogues on ovaries and endometrial receptivity. The main evidence limitation was Imprecision. Conventional GnRH antagonist protocols represent a safer and more cost-effective treatment choice for PCOS women undergoing IVF/ICSI cycles than the standard long GnRH agonist protocol without compromising the IVF/ICSI clinical outcomes. The study had no sources of financial support and was prospectively registered at PROSPERO (International Prospective Register of Systematic Reviews) under registration number (CRD42021242476)." @default.
• W4220900274 created "2022-04-03" @default.
• W4220900274 creator A5031585853 @default.
• W4220900274 creator A5081470198 @default.
• W4220900274 creator A5084039330 @default.
• W4220900274 date "2022-03-15" @default.
• W4220900274 modified "2023-09-30" @default.
• W4220900274 title "Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis" @default.
• W4220900274 cites W1577097214 @default.
• W4220900274 cites W1584942558 @default.
• W4220900274 cites W1967063783 @default.
• W4220900274 cites W1972780889 @default.
• W4220900274 cites W1978193519 @default.
• W4220900274 cites W1980149360 @default.
• W4220900274 cites W1980316802 @default.
• W4220900274 cites W1981916826 @default.
• W4220900274 cites W1985679508 @default.
• W4220900274 cites W1998156482 @default.
• W4220900274 cites W2013675503 @default.
• W4220900274 cites W2014296890 @default.
• W4220900274 cites W2015547081 @default.
• W4220900274 cites W2030382647 @default.
• W4220900274 cites W2031834505 @default.
• W4220900274 cites W2038459220 @default.
• W4220900274 cites W2038753340 @default.
• W4220900274 cites W2042761161 @default.
• W4220900274 cites W2044752015 @default.
• W4220900274 cites W2044969592 @default.
• W4220900274 cites W2045614874 @default.
• W4220900274 cites W2048048668 @default.
• W4220900274 cites W2049175197 @default.
• W4220900274 cites W2058294720 @default.
• W4220900274 cites W2063252447 @default.
• W4220900274 cites W2075773529 @default.
• W4220900274 cites W2081930519 @default.
• W4220900274 cites W2092907352 @default.
• W4220900274 cites W2093826071 @default.
• W4220900274 cites W2094167071 @default.
• W4220900274 cites W2102193467 @default.
• W4220900274 cites W2103247573 @default.
• W4220900274 cites W2104696616 @default.
• W4220900274 cites W2105321597 @default.
• W4220900274 cites W2107529015 @default.
• W4220900274 cites W2113378534 @default.
• W4220900274 cites W2113628599 @default.
• W4220900274 cites W2117212359 @default.
• W4220900274 cites W2117381179 @default.
• W4220900274 cites W2117814169 @default.
• W4220900274 cites W2121274977 @default.
• W4220900274 cites W2121275348 @default.
• W4220900274 cites W2124263439 @default.
• W4220900274 cites W2125625600 @default.
• W4220900274 cites W2130793514 @default.
• W4220900274 cites W2133883611 @default.
• W4220900274 cites W2134915338 @default.
• W4220900274 cites W2135868809 @default.
• W4220900274 cites W2136389184 @default.
• W4220900274 cites W2141252044 @default.
• W4220900274 cites W2142487095 @default.
• W4220900274 cites W2143160897 @default.
• W4220900274 cites W2144290090 @default.
• W4220900274 cites W2149158668 @default.
• W4220900274 cites W2152113349 @default.
• W4220900274 cites W2154559552 @default.
• W4220900274 cites W2162528107 @default.
• W4220900274 cites W2163324898 @default.
• W4220900274 cites W2167117296 @default.
• W4220900274 cites W2167543291 @default.
• W4220900274 cites W2194639637 @default.
• W4220900274 cites W2274609004 @default.
• W4220900274 cites W2276856939 @default.
• W4220900274 cites W2401655965 @default.
• W4220900274 cites W2411305332 @default.
• W4220900274 cites W2461219388 @default.
• W4220900274 cites W2465949309 @default.
• W4220900274 cites W2467710819 @default.
• W4220900274 cites W2734470509 @default.
• W4220900274 cites W2740474653 @default.
• W4220900274 cites W2757065056 @default.
• W4220900274 cites W2808136879 @default.
• W4220900274 cites W2888435803 @default.
• W4220900274 cites W2890819900 @default.
• W4220900274 cites W2891844107 @default.
• W4220900274 cites W2908196557 @default.
• W4220900274 cites W2926770468 @default.
• W4220900274 cites W2929025230 @default.
• W4220900274 cites W2970456857 @default.
• W4220900274 cites W2970684805 @default.
• W4220900274 cites W2972224182 @default.
• W4220900274 cites W3003238214 @default.
• W4220900274 cites W3013245039 @default.
• W4220900274 cites W3118615836 @default.
• W4220900274 cites W3123115618 @default.
• W4220900274 cites W3125971890 @default.
• W4220900274 cites W5004052 @default.
• W4220900274 cites W781642024 @default.
• W4220900274 doi "https://doi.org/10.1038/s41598-022-08400-z" @default.
• W4220900274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35292717" @default.
• W4220900274 hasPublicationYear "2022" @default.
• W4220900274 type Work @default.

• next